Pharmx Wins 5-Year Sigma Alliance Covering 3,000+ Pharmacies and Chemist Warehouse
Pharmx secures landmark alliance with Sigma Healthcare and Chemist Warehouse network
Pharmx Technologies Limited (ASX: PHX) has entered into a binding, multi-year strategic alliance with Sigma Healthcare Limited (ASX: SIG), positioning the company as a core technology infrastructure partner to Sigma and the Chemist Warehouse network. The agreement grants Pharmx preferred Electronic Data Interchange (EDI) service provider status across Sigma’s wholesale operations and Chemist Warehouse retail outlets in Australia and New Zealand.
The scale of access is significant. Sigma currently services over 3,000 pharmacy customers in Australia, including 850 Chemist Warehouse, Amcal and Discount Drug Stores franchises, plus over 90 stores across the Republic of Ireland, UAE and New Zealand. This alliance embeds Pharmx into one of Australia’s largest pharmacy distribution networks during a transformative period following Sigma’s merger with Chemist Warehouse.
Under the agreement, Pharmx becomes the preferred EDI partner for both Sigma wholesale and Chemist Warehouse retail operations across Australia and New Zealand. The parties will also collaborate on global EDI capabilities and a range of digital services designed to modernise pharmacy supply chains and support industry-wide efficiency. Pharmx will continue to operate as an independent, whole-of-market solutions provider for the ANZ pharmacy sector, working across all major wholesalers, suppliers, vendors and pharmacies.
When big ASX news breaks, our subscribers know first
What is EDI and why does it matter for pharmacy supply chains?
Electronic Data Interchange (EDI) is the digital backbone that allows pharmacies, wholesalers and suppliers to exchange orders, invoices and inventory data automatically. Rather than manually processing purchase orders or invoices, EDI systems transmit this information electronically between trading partners in standardised formats, reducing errors and speeding up transaction flows.
Preferred EDI partner status positions Pharmx at the centre of transaction flows across thousands of pharmacies. The company already facilitates approximately $20 billion in transactions annually through its platform, connecting the largest network of pharmacies, suppliers and technology vendors across Australia and New Zealand.
For investors, EDI represents sticky infrastructure. Once embedded in a pharmacy’s ordering and inventory management systems, switching costs are high due to integration complexity and operational disruption. This creates recurring revenue visibility and a durable competitive moat. The strategic alliance extends this infrastructure advantage across Sigma’s entire customer base, including the rapidly expanding Chemist Warehouse network.
Two-part deal structure unlocks immediate value and long-term upside
The strategic alliance initiatives will be delivered across two distinct phases, each carrying material financial and operational implications.
Part A establishes the immediate foundation. Pharmx becomes the preferred EDI partner for Sigma wholesale and Chemist Warehouse retail operations across Australia and New Zealand, directly supporting Sigma’s growth in the New Zealand market. Sigma will renew its existing agreements for the provision of EDI services for its wholesale business for a further 5 years. Sigma will subscribe for approximately 59.95 million Pharmx shares, representing 10% of Pharmx’s issued share capital, and will obtain a seat on the Pharmx Board.
Part B provides expansion optionality. Pharmx will expand the scope of services available to Sigma across additional international markets and new solution areas. Sigma will have the opportunity to subscribe for further Pharmx shares up to an aggregate holding of 19.9% over the term of the alliance, with any such additional issues priced at the 30-day volume weighted average price prior to the relevant issue and subject to Pharmx shareholder approval to the extent required.
In return for entering into the strategic alliance and the long-term commitment to procure services, Pharmx will pay Sigma an establishment fee of approximately $8.7 million. All shares issued to Sigma under the alliance will be subject to a three-year escrow period, demonstrating long-term strategic alignment beyond a typical vendor-customer relationship.
| Deal Component | Part A | Part B |
|---|---|---|
| Scope | Preferred EDI partner ANZ; Sigma wholesale renewal (5 years) | International expansion; new solution areas |
| Equity Investment | 59.95 million shares (10% stake) | Up to 19.9% aggregate (subject to approval) |
| Pricing | Fixed subscription | 30-day VWAP at time of issue |
| Governance | Sigma Board seat | Subject to shareholder approval where required |
| Escrow | 3 years | 3 years |
Sigma’s 10% equity investment and Board seat signal strategic alignment that extends well beyond a standard technology services contract. The escrow provisions reinforce long-term commitment from Sigma, whilst the path to a 19.9% aggregate stake provides ongoing capital access tied directly to service expansion milestones. This structure aligns both parties’ incentives around delivering measurable value across the partnership.
Revenue potential across Gateway, Marketplace and Analytics
The strategic alliance agreement is anticipated to increase revenues across Pharmx’s three core platforms: Gateway, Marketplace and Analytics. However, the incremental financial impact is not quantifiable until future statements of work have been defined and agreed by both parties, according to the company’s announcement.
Pharmx will continue to operate as an independent, whole-of-market solutions provider for the ANZ pharmacy sector. This positioning means the company continues to work across all major wholesalers, suppliers, vendors and pharmacies, rather than operating as an exclusive technology partner to Sigma alone.
The whole-of-market approach provides two strategic advantages. First, it protects against customer concentration risk by maintaining diversified revenue streams across multiple wholesale and retail customers. Second, it positions Pharmx to cross-sell and upsell additional digital services to Sigma’s network without exclusivity constraints that might limit growth with other major pharmacy groups.
The Gateway platform handles core EDI ordering and inventory management. Marketplace provides a digital procurement platform connecting pharmacies with suppliers. Analytics delivers data insights derived from the approximately $20 billion in annual transaction flows processed through the Pharmx platform. Deeper integration with Sigma’s network of over 3,000 pharmacy customers creates opportunities to expand utilisation across all three revenue streams, particularly as collaborative development work under Part B defines new solution areas and international market requirements.
CEO commentary signals transformational milestone
Pharmx CEO Tom Culver described the partnership as representing one of the most strategically significant milestones in the company’s history.
Tom Culver, CEO, Pharmx Technologies
“This partnership represents one of the most strategically significant milestones in Pharmx’s history. Sigma’s decision to deepen its relationship with Pharmx during a period of major transformation following its merger with Chemist Warehouse, signals strong confidence in our technology, our strategy, and our execution. The agreement has the potential to broaden our revenue profile, expand our footprint across ANZ, and establish a foundation for future global expansion. These opportunities result from the investments we have made in strengthening the Gateway, launching Marketplace, and accelerating our analytics strategy. We look forward to partnering closely with Sigma to drive mutual growth and long-term value for Pharmx shareholders.”
Sigma CEO Vikesh Ramsunder reinforced the strategic rationale, noting that the partnership moves beyond a traditional vendor-customer relationship to a scalable partnership that reduces complexity, enhances supply chain performance, drives deeper data analytics insights, and creates value and growth opportunities for both organisations. The progress of Pharmx’s product suite and the alignment of both companies’ growth objectives made this a compelling strategic fit, according to Ramsunder’s statement.
Management’s framing as a “transformational” milestone elevates investor expectations for future strategic announcements. Sigma CEO’s explicit endorsement validates Pharmx’s technology platform and growth trajectory during a period of major industry consolidation following the Sigma-Chemist Warehouse merger.
The next major ASX story will hit our subscribers first
Next steps and timeline
Part A of the expanded partnership will commence on 23 February 2026, with deliverables under this phase of the agreement to begin shortly thereafter. The immediate commencement demonstrates deal readiness and execution capability.
Pharmx will hold an investor briefing at 2pm on Monday 23 February 2026 to discuss the strategic alliance. The briefing provides an opportunity for management to address market questions directly and detail implementation plans for both Part A and Part B of the agreement.
Shareholders can direct questions via email to investor.relations@pharmx.com.au. Part B deliverables will be defined through future statements of work agreed between both parties, with timing dependent on collaborative development work across international markets and new solution areas.
The key milestones are:
- Part A commencement: 23 February 2026
- Investor briefing: 2pm, 23 February 2026
- Part B: Future statements of work to be agreed
The strategic alliance agreement is subject to standard termination provisions. Sigma’s equity investment, Board representation and three-year escrow commitment position this as a long-term strategic partnership rather than a transactional technology services contract.
Want the Next Healthcare Tech Winner in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to receive healthcare and technology alerts the moment market-moving announcements drop.